Taysha Gene Therapies Inc (NAS:TSHA)
$ 2.06 -0.09 (-4.19%) Market Cap: 413.83 Mil Enterprise Value: 369.69 Mil PE Ratio: 0 PB Ratio: 7.09 GF Score: 31/100

Taysha Gene Therapies Inc at Chardan Genetic Medicines Conference (Virtual) Transcript

Oct 05, 2021 / 05:30PM GMT
Release Date Price: $19.13 (+2.96%)
Geulah Livshits
Chardan Capital - Analyst

Hello, and it's now my pleasure to introduce our next fireside chat guest. From Taysha Gene Therapies, we have RA Session, President, Chief Executive Officer and Founder; Kamran Alam, CFO; and Dr. Suyash Prasad, CMO and Head of R&D at Taysha Gene Therapies. (Operator Instructions) Thank you again to our guests for joining us today.

So to start off, RA, maybe you could provide us with a couple minutes of introductory comments on Taysha, including any recent business developments like from today for example, and on this upcoming milestone.

RA Session
Taysha Gene Therapies, Inc. - President, Founder and CEO

Sure, I'm happy to do so, and Geulah, thanks for having us. We're always excited to interact with you and the Chardan team. You guys have been great supporters of the story from the early beginning, and so we really appreciate the support.

So really Taysha is a company that is built on a foundational collaboration with UT Southwestern, which we expanded on earlier today with the announcement of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot